RxDoctor Payments Data

Wendy Garrett, MD

Internal Medicine · Boston, MANPI 1487625463

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,974 of the $15,004 with a category attached, or 99.8%. Sanofi Pasteur Inc. accounts for 61.3% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $9,227, 2.7 times the $3,452 reported in 2020. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,004in general payments, 2019–2025

Across 5 payments — averaging $3000.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$9K
  • Sanofi$3K
  • GSK$2K
  • Astellas Pharma Inc$600
  • AbbVie$31
$586,182in research payments, 2019–2025

Across 5 payments — averaging $117,236 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$586K
  • Takeda Pharmaceuticals U.S.A., Inc.$650

What the payments were for

  • Consulting fees$14,974100%
  • Food & beverage$310%

General payments by program year

20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi Pasteur Inc.1$9,196
Sanofi1$3,452
GSK1$1,726
Astellas Pharma Inc1$600
AbbVie1$31

How this compares

$15,004 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$7,620
Medicare patients
19
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →